Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8303MR)

This product GTTS-WQ8303MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8303MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14484MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ15623MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ1050MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ11012MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ4287MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ6668MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ3689MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ11404MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW